Literature DB >> 7771626

Changes in the surgical management of esophageal cancer from 1970 to 1993.

S G Swisher1, K K Hunt, E C Holmes, M J Zinner, D W McFadden.   

Abstract

PURPOSE: To evaluate the changes since 1970 in the management and outcome of esophageal resection for cancer.
METHODS: The records of all 316 patients who underwent esophageal resection for cancer at University of California Los Angeles Medical Center during the years 1970 to 1993 were reviewed.
RESULTS: When records from 1984 to 1993 were compared to those from 1970 to 1983, significant decreases were seen in operative mortality (10% to 3%, P < 0.01), morbidity (72% to 60%, P < 0.05), anastomotic leaks (12% to 5%, P < 0.03), and reoperations (20% to 8%, P < 0.003). Time spent in hospital and in intensive care decreased 40%. These improvements in short-term outcome were most evident in patients with disease in later stages. The 5-year survival rate increased (12% to 21%, P < 0.01). A greater percentage of tumors presented in early stages (21% versus 37%).
CONCLUSIONS: Short-term outcome of surgical resection for esophageal carcinoma improved between 1970 and 1993, in part because of changes in perioperative and surgical management. Long-term survival improved, probably due to earlier detection of tumors.

Entities:  

Mesh:

Year:  1995        PMID: 7771626     DOI: 10.1016/s0002-9610(99)80231-1

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  18 in total

Review 1.  Should we continue oesophageal surgery in a district general hospital? A review of 200 consecutive cases.

Authors:  G H Dickson; R Waters; J Bull; V Kaul; J Sitzia
Journal:  Ann R Coll Surg Engl       Date:  2001-05       Impact factor: 1.891

2.  Randomized study of the benefits of preoperative corticosteroid administration on the postoperative morbidity and cytokine response in patients undergoing surgery for esophageal cancer.

Authors:  Nobuhiro Sato; Keisuke Koeda; Kenichiro Ikeda; Yusuke Kimura; Kiichi Aoki; Takeshi Iwaya; Yuji Akiyama; Kaoru Ishida; Kazuyoshi Saito; Shigeatsu Endo
Journal:  Ann Surg       Date:  2002-08       Impact factor: 12.969

3.  The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia.

Authors:  M J Edwards; D R Gable; A B Lentsch; J D Richardson
Journal:  Ann Surg       Date:  1996-05       Impact factor: 12.969

Review 4.  Should esophageal resections for cancer be performed in high-volume centers only?

Authors:  Carlo V Feo; Victoria M Villaflor; Marco G Patti
Journal:  Updates Surg       Date:  2011-06-22

5.  Transthoracic versus transhiatal esophagectomy for esophageal carcinoma: experience from a single tertiary care institution.

Authors:  Nadeem UlNazeer Kawoosa; Abdul Majeed Dar; Mukand Lal Sharma; Abdul Gani Ahangar; Ghulam Nabi Lone; Mohammad Akbar Bhat; Shyam Singh
Journal:  World J Surg       Date:  2011-06       Impact factor: 3.352

6.  Association of angiotensin-converting enzyme insertion/deletion polymorphism with serum level and development of pulmonary complications following esophagectomy.

Authors:  Jang-Ming Lee; An-Chi Lo; Shi-Yi Yang; Huei-Shian Tsau; Robert J Chen; Yung-Chie Lee
Journal:  Ann Surg       Date:  2005-04       Impact factor: 12.969

7.  Determination of urinary trypsin inhibitor provides insight into postoperative complications in patients following esophagectomy.

Authors:  Ichiro Akagi; Masao Miyashita; Ken Takahashi; Takeshi Matsutani; Akihisa Matsuda; Tsutomu Nomura; Hiroshi Makino; Nobutoshi Hagiwara; Eiji Uchida
Journal:  Exp Ther Med       Date:  2012-04-18       Impact factor: 2.447

8.  An analysis of the factors contributing to a reduction in the incidence of pulmonary complications following an esophagectomy for esophageal cancer.

Authors:  Masaki Nakamura; Makoto Iwahashi; Mikihito Nakamori; Koichiro Ishida; Teiji Naka; Takeshi Iida; Masahiro Katsuda; Toshiaki Tsuji; Yoshihiro Nakatani; Hiroki Yamaue
Journal:  Langenbecks Arch Surg       Date:  2007-12-11       Impact factor: 3.445

9.  Neoadjuvant chemoradiotherapy for esophageal cancer using weekly Paclitaxel and Carboplatin plus infusional 5-Fluorouracil.

Authors:  David E Gannett; Ron F Wolf; Gary W Takahashi; Jeannie Louie; Rick C Wagner; Fred S Ey; Michael M Owens; William E Johnson; David W Cook; Roger E Alberty
Journal:  Gastrointest Cancer Res       Date:  2007-07

Review 10.  Gastroesophageal junction adenocarcinoma.

Authors:  S G Swisher; P W Pisters; R Komaki; S Lahoti; J A Ajani
Journal:  Curr Treat Options Oncol       Date:  2000-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.